1. Search Result
Search Result
Results for "

tuberculosis

" in MCE Product Catalog:

176

Inhibitors & Agonists

19

Natural
Products

1

Recombinant Proteins

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-146348
    Tuberculosis inhibitor 5

    Bacterial Infection
    Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent.
  • HY-115900
    Tuberculosis inhibitor 4

    Bacterial Infection
    Tuberculosis inhibitor 4 (compound 16), a mandelic acid-based spirothiazolidinone, has potent antimycobacterial activity against Mycobacterium tuberculosis strain H37Rv with the high inhibition value 98% at lower than 6.25 µg/mL concentration.
  • HY-114147
    Tuberculosis inhibitor 3

    Bacterial Infection Inflammation/Immunology
    Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 µg/mL) against drug-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability.
  • HY-119938
    Tuberculosis inhibitor 1

    Bacterial Infection
    Tuberculosis inhibitor 1 is a potent and non-cytotoxic trypanosoma brucei growth inhibitor with an EC50 of 5 nM.
  • HY-134648
    GSK3036656

    GSK070

    Bacterial Infection
    GSK3036656 (GSK070) is a potent, selective and orally active inhibitor of M. tuberculosis leucyl-tRNA synthetase, with an IC50 of 0.20 μM. GSK3036656 can be used for the research of tuberculosis.
  • HY-150967
    MmpL3-IN-1

    Bacterial Infection
    MmpL3-IN-1 (compound 32) is a potent Mycobacterial membrane protein large 3 (MmpL3) inhibitor. MmpL3-IN-1 has anti-tuberculosis activity with the MIC<0.016 μg/mL in M. tuberculosis and can be used in studies of drug-resistant tuberculosis.
  • HY-147661
    DHFR-IN-2

    Antifolate Infection
    DHFR-IN-2 (compound 4e) is a potent and uncompetitive inhibitor for MtDHFR (dihydrofolate reductase from M. tuberculosis), with an IC50 of 7 μM. DHFR-IN-2 can be used for tuberculosis (TB) research.
  • HY-128866
    TBAJ-876

    Bacterial Infection
    TBAJ-876 is the inhibitor of mycobacterium tuberculosis. TBAJ-876 is the analogue of the anti-tuberculosis drug Bedaquiline. TBAJ-876 has the potential for the research of tuberculosis.
  • HY-146555
    Antitubercular agent-14

    Bacterial Infection
    Antitubercular agent-14 (Compound 1) is an antitubercular agent with an MIC of 0.3 µg/mL against M. tuberculosis.
  • HY-147000
    DNA Gyrase-IN-1

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-1 (compound 42) is a potent and selective DNA gyrase inhibitor with an IC50 value of 2.6 µM. DNA Gyrase-IN-1 has high inhibitory activity against Mycobacterium tuberculosis (Mtb) with MIC of 0.49 µM. DNA Gyrase-IN-1 can be used for researching tuberculosis.
  • HY-146700
    MtTMPK-IN-6

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-6 (compound 1) is a potent M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 29 μM. MtTMPK-IN-6 can be used for researching tuberculosis.
  • HY-146699
    MtTMPK-IN-5

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-5 (compound 17) is a potent M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 34 μM. MtTMPK-IN-5 combines favorable enzyme inhibitory activity with significant activity against M. tuberculosis (MIC = 12.5 μM). MtTMPK-IN-5 can be used for researching tuberculosis.
  • HY-147047
    InhA-IN-2

    Bacterial Infection
    InhA-IN-2 (Compound 23) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 0.31 μM.
  • HY-146702
    MtTMPK-IN-8

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-8 (compound 27) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor. MtTMPK-IN-8 has sub-micromolar activity against mycobacteria (MICs = 0.78~9.4 μM) without significant cytotoxicity. MtTMPK-IN-8 can be used for researching tuberculosis.
  • HY-139618
    Dup-721

    Bacterial Antibiotic Infection
    DuP-721 is a broad spectrum and orally active antibacterial agent against a variety of clinically susceptible and resistant bacteria, especially M. tuberculosis.
  • HY-146701
    MtTMPK-IN-7

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-7 (compound 26) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 47 μM. MtTMPK-IN-7 has sub-micromolar activity against mycobacteria (MICs = 2.3~4.7 μM) without significant cytotoxicity. MtTMPK-IN-7 can be used for researching tuberculosis.
  • HY-146703
    MtTMPK-IN-9

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-9 (compound 28) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 48 μM. MtTMPK-IN-9 has sub-micromolar activity against mycobacteria (MICs = 6.25~9.4 μM) without significant cytotoxicity. MtTMPK-IN-9 can be used for researching tuberculosis.
  • HY-115883
    PptT-IN-2

    Others Infection Inflammation/Immunology
    PptT-IN-2 (compound 5k) is a potent inhibitor of with phosphopantetheinyl phosphoryl transferase (PptT) an IC50 of 2.5 μM. Phosphopantetheinyl transferase, an essential enzyme that plays a critical role in the biosynthesis of cellular lipids and virulence factors in Mycobacterium tuberculosis. PptT-IN-2 has the potential for the research of tuberculosis.
  • HY-115884
    PptT-IN-3

    Others Infection Inflammation/Immunology
    PptT-IN-3 (compound 5p) is a potent inhibitor of with phosphopantetheinyl phosphoryl transferase (PptT) an IC50 of 3.5 μM. Phosphopantetheinyl transferase, an essential enzyme that plays a critical role in the biosynthesis of cellular lipids and virulence factors in Mycobacterium tuberculosis. PptT-IN-3 has the potential for the research of tuberculosis.
  • HY-115882
    PptT-IN-1

    Others Infection Inflammation/Immunology
    PptT-IN-1 (compound 5j) is a potent inhibitor of with phosphopantetheinyl phosphoryl transferase (PptT) an IC50 of 2.8 μM. Phosphopantetheinyl transferase, an essential enzyme that plays a critical role in the biosynthesis of cellular lipids and virulence factors in Mycobacterium tuberculosis. PptT-IN-1 has the potential for the research of tuberculosis.
  • HY-146104
    Antimycobacterial agent-1

    Bacterial Infection
    Antimycobacterial agent-1 (compound 33) has selectively antimycobacterial activity against Mycobacterium tuberculosis (M. tuberculosis) H37Ra with a MIC value of 1 μg/ml. Antimycobacterial agent-1 has relatively low cytotoxicity in normal cells (Vero cells IC50 = 143.2 μg/ml).
  • HY-B0271
    Pyrazinamide

    Pyrazinecarboxamide; Pyrazinoic acid amide

    Bacterial Autophagy Antibiotic Infection
    Pyrazinamide (Pyrazinecarboxamide; Pyrazinoic acid amide) is a potent and orally active antitubercular antibiotic. Pyrazinamide is a prodrug that is converted to the active form pyrazinoic acid (POA) by PZase/nicotinamidase encoded by the pncA gene in M. tuberculosis.
  • HY-13579
    BTZ043

    Bacterial Antibiotic Infection
    BTZ043 is an inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), with MICs of of 2.3 nM and 9.2 nM for M. tuberculosis H37Rv and Mycobacterium smegmatis, respectively.
  • HY-124781
    ML406

    Bacterial Antibiotic Infection
    ML406 is a small molecule probe that shows anti-tubercular activity via M.tuberculosis BioA (DAPA synthase) enzyme inhibition with an IC50 of 30 nM. M.tuberculosis BioA is an enzyme involved in biotin biosynthesis in M.tuberculosis.
  • HY-134940
    OPC-167832

    Bacterial Infection Inflammation/Immunology
    OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis.
  • HY-124814
    C215

    Bacterial Infection
    C215 is a potent inhibitor of MmpL3. C215 is identified in HTS with glycerol independent activity against M. tuberculosis, limited non-specific toxicity against mammalian cells, an IC90 of 16 μM against M. tuberculosis, and efficacy against M. tuberculosis growing in macrophages.
  • HY-144663
    MtTMPK-IN-1

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-1 (compound 3) is a potent Mycobacterium tuberculosis thymidylate kinase (MtTMPK) inhibitor with an IC50 value of 2.5 μM. MtTMPK-IN-1 has moderate to weak activity against Mtb H37Rv and low cytotoxicity in human fibroblast cells MRC-5. MtTMPK-IN-1 can be used for researching tuberculosis.
  • HY-146057
    Antituberculosis agent-2

    Bacterial Infection
    Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against drug-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 µg/mL against M. tuberculosis H37Rv, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability.
  • HY-138671
    DprE1-IN-4

    Bacterial Infection
    DprE1-IN-4 is a potent and orally active noncovalent DprE1 inhibitor with an IC50 of 0.90 μg/mL. DprE1-IN-4 exhibits potent in vitro activity against M. tuberculosis H37Rv and drug-resistant tuberculosis strain with MIC values of 0.12 μg/mL and 0.24 μg/mL, respectively. DprE1-IN-4 displays acceptable pharmacokinetic property and shows significant bactericidal activity in an acute mouse model of tuberculosis.
  • HY-141715
    BRD-8000.3

    Others Infection
    BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity. BRD-8000.3 can be used for the research of tuberculosis.
  • HY-144664
    MtTMPK-IN-2

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-2 (compound 15) is a potent Mycobacterium tuberculosis thymidylate kinase (MtTMPK) inhibitor with an IC50 value of 1.1 μM. MtTMPK-IN-2 has inhibitory activity against Mtb H37Rv (MIC = 12.5 μM). MtTMPK-IN-2 exhibits certain cytotoxicity in human fibroblast cells MRC-5 (EC50 = 6.1 μM). MtTMPK-IN-2 can be used for researching tuberculosis.
  • HY-144665
    MtTMPK-IN-3

    Bacterial Thymidylate Synthase Infection
    MtTMPK-IN-3 (compound 25) is a potent Mycobacterium tuberculosis thymidylate kinase (MtTMPK) inhibitor with an IC50 value of 0.12 μM. MtTMPK-IN-3 has inhibitory activity against Mtb H37Rv (MIC = 12.5 μM). MtTMPK-IN-3 exhibits certain cytotoxicity in human fibroblast cells MRC-5 (EC50 = 12.5 μM). MtTMPK-IN-3 can be used for researching tuberculosis.
  • HY-125965
    BioA-IN-13

    Bacterial Infection
    BioA-IN-13 is a potent, cell permeable and whole-cell active inhibitor of Mycobacterium tuberculosis BioA enzyme.
  • HY-10392
    Sutezolid

    PNU-100480; U-100480; PF-02341272

    Bacterial Antibiotic Infection
    Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis.
  • HY-139595
    Polyketide synthase 13-IN-2

    Bacterial Infection Inflammation/Immunology
    Polyketide synthase 13-IN-2 (comp 42) is a polyketide synthase 13 inhibitor against Mycobacterium tuberculosis, with an MIC of 0.25 μg/mL.
  • HY-146158
    WX-081

    Bacterial Potassium Channel Antibiotic Infection
    WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for drug susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.
  • HY-117145
    Thiophene-2

    TP2

    Bacterial Infection
    Thiophene-2 (TP2) is a specific polyketide synthase 13 (Pks13) inhibitor. Thiophene-2 inhibits mycolic acid biosynthesis and rapidly leads to mycobacterial cell death. Thiophene-2 is active against Mycobacterium tuberculosis with a MIC value of 1 μM, and has potent anti-tuberculosis activity.
  • HY-150589
    InhA-IN-4

    Bacterial Infection
    InhA-IN-4 (TU14) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 15.6 μM.
  • HY-146374
    Antibacterial agent 96

    Bacterial Infection
    Antibacterial agent 96 (compound 4k) is a potent antibacterial agent. Antibacterial agent 96 shows antitubercular activity against drug-susceptible and multidrug-resistantMycobacterium tuberculosis (M. tuberculosis) strains. Antibacterial agent 96 shows toxicity to HepG2 and Vero cells.
  • HY-146055
    Antituberculosis agent-1

    Bacterial Infection
    Antituberculosis agent-1 (Compound 8a) is an antituberculosis agent with an MIC of 3.84 µg/mL against M. tuberculosis H37Rv.
  • HY-150588
    InhA-IN-3

    Bacterial Infection
    InhA-IN-3 (Compound TU12) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 17.7 μM.
  • HY-147017
    GSK2556286

    GSK286

    Bacterial Infection Inflammation/Immunology
    GSK2556286 (GSK286) is an orally active inhibitor of M. tuberculosis. GSK2556286 inhibits growth within human macrophages (IC50 = 0.07 μM). GSK2556286 is effective against both multidrug-resistant (MDR) or extensively drug-resistant (XDR) and drug-sensitive (DS) M. tuberculosis.
  • HY-146051
    Antitubercular agent-18

    Bacterial Infection
    Antitubercular agent-18 (Compound 9a) is an antitubercular agent with MIC values of 2, 2, 2 and 128 µg/ml against M. tuberculosis H37Rv, Spec. 192, Spec 210 and Spec. 800, respectively. Antitubercular agent-18 shows highly selective antimycobacterial effects.
  • HY-146050
    Antitubercular agent-17

    Bacterial Infection
    Antitubercular agent-17 (Compound 8a) is an antitubercular agent with MIC values of 2, 2, 2 and 128 µg/ml against M. tuberculosis H37Rv, Spec. 192, Spec 210 and Spec. 800, respectively. Antitubercular agent-17 shows highly selective antimycobacterial effects.
  • HY-136348
    ML338

    Bacterial Infection
    ML338 is a selective small molecule inhibitor probe of non-replicating Mycobacterium tuberculosis bacilli and is against the non-replicating M. tuberculosis with IC90 and IC99 values of 1 μM and 4 μM, respectively by CFU. ML338 is a invaluable tool for identifying both essential functions and vulnerabilities of the M. tuberculosis bacilli in the nutrient deprivation states. ML338 can be used for the study of M. tuberculosis chemotherapy.
  • HY-129943
    Benzothiohydrazide

    Bacterial Infection
    Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC1 and IC2).
  • HY-139596
    Polyketide synthase 13-IN-3

    Others Infection Inflammation/Immunology
    Polyketide synthase 13-IN-3 (compound 41) is a polyketide synthase 13 inhibitor,with a MIC of 0.0625-0.125 μg/mL against the M. tuberculosis strain H37Rv.
  • HY-144325
    CYP121A1-IN-1

    Cytochrome P450 Infection
    CYP121A1-IN-1 is a potent CYP121A1 inhibitor with favorable activity against Mycobacterium tuberculosis (H37Rv MIC90∼6.25 μM, ∼2.2 μg/mL). CYP121A1-IN-1 can markedly reduce the production of mycocyclosin via inhibiting the CYP121A1 mediated turnover of cyclo(l-tyrosyl-l-tyrosyl) to mycocyclosin.
  • HY-146119
    Antitubercular agent-24

    Bacterial Infection
    Antitubercular agent-24 (Compound 1) is an anti-tubercular agent with an extracellular IC50 of 0.83 μM and an intracellular IC50 of 0.17 μM against M. tuberculosis H37Rv.
  • HY-139398
    TBI-223

    Bacterial Infection
    TBI-223 is an orally bioavailable oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb).
  • HY-20457
    TL8-506

    Toll-like Receptor (TLR) Inflammation/Immunology
    TL8-506 is a specific TLR8 agonist with an EC50 of 30 nM. TL8-506 can be used for the research of tuberculosis and autoimmune diseases.
  • HY-145985
    CBR-3465

    Bacterial Infection
    CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.
  • HY-145986
    CBR-6672

    Bacterial Infection
    CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.
  • HY-12904
    TCA1

    Bacterial Infection
    TCA1 is a small molecule with activity against drug-susceptible and -resistant Mycobacterium tuberculosis (Mtb). TCA1 inhibits enzymes involved in cell wall and molybdenum cofactor biosynthesis, such as DprE1 and MoeW.
  • HY-N1160
    Tetrahydroxysqualene

    Bacterial Infection
    Tetrahydroxysqualene is a triterpene, possessing antimycobacterial activity against Mycobacterium tuberculosis with an MIC of 10.0 μg/mL. Tetrahydroxysqualene can be isolated from the methanolic extracts of Rhus taitensis Guill.
  • HY-145741
    MptpB-IN-1

    Antibiotic Infection
    MptpB-IN-1 (Compound 13) is a potent and orally active inhibitor of MptpB. Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host. MptpB-IN-1 reduces multidrug-resistant mycobacterium tuberculosis survival and infection burden.
  • HY-146298
    Mt KARI-IN-1

    Bacterial Infection
    Mt KARI-IN-1 (Lead compound) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a Ki value of 3.06 μM.
  • HY-44688
    S.pombe lumazine synthase-IN-1

    Bacterial Fungal Infection
    S.pombe lumazine synthase-IN-1 is an inhibitor of lumazine synthases with Ki values of 243 μM and 9.6 μM for Schizosaccharomyces pombe and Mycobacterium tuberculosis lumazine synthases, respectively.
  • HY-B0030
    D-Cycloserine

    iGluR Bacterial Antibiotic Infection Neurological Disease
    D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research.
  • HY-B0963
    Cloxiquine

    5-Chloro-8-quinolinol

    Bacterial Fungal Parasite PPAR Cancer Infection
    Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ.
  • HY-101867
    AU1235

    Bacterial Cancer Infection
    AU1235, an adamantyl urea, is a potent MmpL3 inhibitor. The Mycobacterium tuberculosis protein MmpL3 performs an essential role in cell wall synthesis, since it effects the transport of trehalose monomycolates across the inner membrane.
  • HY-145931
    CC214-2

    mTOR Cancer
    CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB.
  • HY-139987A
    LeuRS-IN-1 hydrochloride

    Bacterial Infection
    LeuRS-IN-1 hydrochloride is a potent, orally active M. tuberculosis leucyl-tRNA synthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 hydrochloride has IC50 and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively. LeuRS-IN-1 hydrochloride inhibits human cytoplasmic LeuRS (IC50=38.8 μM), and HepG2 protein synthesis (EC50=19.6 μM).
  • HY-139987
    LeuRS-IN-1

    Bacterial Infection
    LeuRS-IN-1 is a potent, orally active M. tuberculosis leucyl-tRNA synthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 has IC50 and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively. LeuRS-IN-1 inhibits human cytoplasmic LeuRS (IC50=38.8 μM), and HepG2 protein synthesis (EC50=19.6 μM).
  • HY-146120
    Antitubercular agent-25

    Bacterial Infection
    Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv. Antitubercular agent-25 exhibits good metabolic stability.
  • HY-143452
    MtTMPK-IN-4

    Tyrosinase Bacterial Inflammation/Immunology
    MtTMPK-IN-4 (compound 2), a para-piperidine, is a potent mycobacterium tuberculosis thymidylate kinase (MtTMPK) inhibitor with an IC50 of 6.1 μM. MtTMPK-IN-4 is a potent tyrosinase inhibitor. MtTMPK-IN-4 is a potent antibacterial agent.
  • HY-122643
    NITD-916

    Bacterial Infection
    NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active and highly lipophilic mycobacterial enoyl reductase InhA inhibitor with an IC50 of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 has potent anti-tuberculosis effects.
  • HY-146557
    Antitubercular agent-16

    Bacterial Infection
    Antitubercular agent-16 (Compound 5q) is an antitubercular agent with MIC90 values of 0.40, 20.11, 23.51, 19.62, 10.93 and 13.62 μg/mL against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152 and CF161, respectively. Antitubercular agent-16 shows low cytotoxicity against macrophages and pulmonary fibroblasts.
  • HY-146556
    Antitubercular agent-15

    Bacterial Infection
    Antitubercular agent-15 (Compound 5n) is an antitubercular agent with MIC90 values of 0.73, 7.69, 9.38, 18.80, 7.53 and 7.31 μg/mL against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152 and CF161, respectively. Antitubercular agent-15 shows low cytotoxicity against macrophages and pulmonary fibroblasts.
  • HY-147818
    DNA Gyrase-IN-2

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-2 (Compound 22a) is a bacterial DNA gyrase B inhibitor with IC50s of 3.29-10.49 and 4.41-5.61 µM for E. coli DNA gyrase and M. tuberculosis DNA gyrase. Anti-tubercular and antibacterial activity.
  • HY-146299
    Mt KARI-IN-2

    Bacterial Infection
    Mt KARI-IN-2 (compound 5b) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a Ki value of 2.02 μM. Mt KARI-IN-2 has inhibitory activity against Mtb H37Rv (MIC = 0.78 μM) and low cytotoxicity (HEK IC50 > 86 μg/mL).
  • HY-146300
    Mt KARI-IN-4

    Bacterial Infection
    Mt KARI-IN-4 (compound 5c) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a Ki value of 5.48 μM. Mt KARI-IN-4 has inhibitory activity against Mtb H37Rv (MIC = 0.78 μM) and low cytotoxicity (HEK IC50 > 72 μg/mL).
  • HY-146301
    Mt KARI-IN-5

    Bacterial Infection
    Mt KARI-IN-5 (compound 6c) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a Ki value of 4.72 μM. Mt KARI-IN-5 has inhibitory activity against Mtb H37Rv (MIC = 1.56 μM) and low cytotoxicity (HEK IC50 > 64 μg/mL)
  • HY-150554
    Antitubercular agent-29

    Bacterial Infection
    Antitubercular agent-29 (compound 6xa) is a potent drug resistant (DR) Mycobacterium tuberculosis (Mtb) inhibitor with MIC of 0.03 µg/mL against drug-susceptible (DS)-Mtb strains, MIC of 0.03-0.06 µg/mL against DR-Mtb strains, and favourable selectivity (SI>40) against Vero cells.
  • HY-147505
    Antitubercular agent-21

    Bacterial Fungal Infection
    Antitubercular agent-21 (Compound 15) is an antitubercular agent with an MIC of o.4 µg/mL against M. tuberculosis H37Rv. Antitubercular agent-21 exhibits lower activity against other microorganism such as bacteria gram-positive, gram-negative or fungi. Antitubercular agent-21 shows low cytotoxicity.
  • HY-125365
    Rifamycin S

    Bacterial Reactive Oxygen Species Antibiotic Infection
    Rifamycin S, a quinone, is an antibiotic against Gram-positive bacteria (including MRSA). Rifamycin S is the oxidized forms of a reversible oxidation-reduction system involving two electrons. Rifamycin S generates reactive oxygen species (ROS) and inhibits microsomal lipid peroxidation. Rifamycin S can be used for tuberculosis and leprosy.
  • HY-B1906
    Streptomycin

    Agrept; Agrimycin; Streptomycin A

    Antibiotic Bacterial Infection Neurological Disease
    Streptomycin (STR), a aminoglycoside group molecular, is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin (STR) also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin (STR), as a basic molecule, can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
  • HY-146121
    Antitubercular agent-26

    Bacterial Infection
    Antitubercular agent-26 (Compound 32) is an orally active anti-tubercular agent with an extracellular IC50 of 0.50 μM and an intracellular IC50 of 0.51 μM against M. tuberculosis H37Rv. Antitubercular agent-26 shows good metabolic stability, low risk of cardiotoxicity and no genotoxicity.
  • HY-146388
    Mtb ATP synthase-IN-1

    Bacterial ATP Synthase Infection
    Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC50 > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium.
  • HY-146098
    Antibacterial agent 105

    Bacterial Antibiotic Infection
    Antibacterial agent 105 (Compound 17) is a phenanthrolinic analog of quinolones show antibacterial activity against M. tuberculosis with antibacterial activity (MIC90=2.64 μM)。Antibacterial agent 105 exhibits antibacterial activities against different bacterial species with MIC90s of 11.18, 11.18,0.70,1.40,44.70, and 22.35 μM for M. smegmatis, M. aurum, M. marinum,BCG, E. aerogenes and S. aureus, respectively.
  • HY-I0447
    4-Aminosalicylic acid

    Bacterial Antibiotic Infection Inflammation/Immunology
    4-Aminosalicylic acid (ASA) is an orally active antibiotic and has the potential to treat tuberculosis.
  • HY-146446
    PXYC1

    Bacterial Antibiotic Infection
    PXYC1 is a ribosomal protein S1 (RpsA) antagonist with Kds of 0.81 and 0.31 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-146451
    PXYC12

    Bacterial Antibiotic Infection
    PXYC12 is a ribosomal protein S1 (RpsA) antagonist with Kds of 2.67 and 4.67 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-146450
    PXYC2

    Bacterial Antibiotic Infection
    PXYC2 is a ribosomal protein S1 (RpsA) antagonist with Kds of 6.35 and 5.11 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-146447
    PXYC13

    Bacterial Antibiotic Infection
    PXYC13 is a ribosomal protein S1 (RpsA) antagonist with Kds of 7.61 and 8.50 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-146449
    PXYD4

    Bacterial Antibiotic Infection
    PXYD4 is a ribosomal protein S1 (RpsA) antagonist with Kds of 3.24 and 1.64 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-147883
    Antitubercular agent-27

    Bacterial Infection
    Antitubercular agent-27 (compound 1) is a potent antitubercular agent with an IC50 value of 3.2 µM, an MIC value of 7.8 µM, an IC90 value of 7.0 µM. Antitubercular agent-27 shows antimycobacterial activity for resistant isolates of Mycobacterium tuberculosis H37Rv. Antitubercular agent-27 shows effective intracellular antimycobacterial activity and low cytotoxicity.
  • HY-147884
    Antitubercular agent-28

    Bacterial Infection
    Antitubercular agent-28 (compound 2) is a potent antitubercular agent with an IC50 value of 1.5 µM, an MIC value of 4.5 µM, an IC90 value of 2.5 µM. Antitubercular agent-28 shows antimycobacterial activity for resistant isolates of Mycobacterium tuberculosis H37Rv. Antitubercular agent-28 shows effective intracellular antimycobacterial activity and low cytotoxicity.
  • HY-147704
    Antimycobacterial agent-2

    Bacterial Infection
    Antimycobacterial agent-2 (compound 58) is a potent antimycobacterial agent. Antimycobacterial agent-2 shows anti-mycobacterial activities with an MIC99 of 0.8 µM for Mycobacterium tuberculosis (M.tb) H37Rv. Antimycobacterial agent-2 shows cytotoxic activities with an IC50 of48.1 µM for CHO cells.
  • HY-125060
    Viridicatin

    Antibiotic Endogenous Metabolite Infection
    Viridicatin is a fungal metabolite from Penicillium species. Viridicatin shows slight in vitro antibiotic activity against Mycobacterium tuberculosis.
  • HY-120733
    Calpinactam

    FKI-4905

    Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    Calpinactam (FKI-4905), a fungal metabolite, is a new anti-mycobacterial agent.Calpinactam is active only against Mycobacteria among various microorganisms, including Gram-positive and Gram-negative bacteria, fungi and yeasts. Calpinactam inhibits the growth of Mycobacterium smegmatis and Mycobacterium tuberculosis with MIC values of 0.78 and 12.5 μg/ml, respectively.
  • HY-12485
    TBA-354

    Bacterial Antibiotic Infection
    TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains.
  • HY-125785A
    2-Mercaptopyridine N-oxide sodium

    Bacterial Infection
    2-Mercaptopyridine N-oxide sodium has bactericidal effect and is against a standard strain of Mycobacterium tuberculosis H37Rv (ATCC 27294) with MIC90 of 7.20 μM. 2-Mercaptopyridine N-oxide sodium and its complex with iron, gallium, and bismuth have good anti-M. tuberculosis activity. 2-Mercaptopyridine N-oxide sodium has potential for the treatment of tuberculosis.
  • HY-144341
    DprE1-IN-1

    Bacterial Infection
    DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both drug-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs<0.1 μg/mL, as well as good intracellular antimycobacterial activity with a 1.29 log10 CFU reduction in macrophages.
  • HY-146373
    Antibacterial agent 95

    Bacterial Infection
    The minimum inhibitory concentration (MIC) of a new 2- (quinoline-4-methoxy) acetamide antituberculotic agent against the reference strain of Mycobacterium tuberculosis H37Rv was as low as 0.3 μ M. It also inhibited the growth of Mycobacterium tuberculosis in the macrophage model of tuberculosis infection.
  • HY-14881
    Bedaquiline

    TMC207; R207910

    Bacterial Antibiotic Infection
    Bedaquiline (TMC207) is a diarylquinoline drug and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-drug resistant tuberculosis.
  • HY-B1355A
    Oxyphenbutazone

    COX Bacterial Cancer Infection Inflammation/Immunology
    Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.
  • HY-14881S2
    Bedaquiline impurity 2-d6

    Bacterial Antibiotic Infection
    Bedaquiline impurity 2-d6 is deuterium labeled Bedaquiline. Bedaquiline (TMC207) is a diarylquinoline drug and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-drug resistant tuberculosis.
  • HY-113289
    Brassicasterol

    Androgen Receptor HSV Bacterial Drug Metabolite Cancer Infection
    Brassicasterol, a metabolite of Ergosterol, plays a role in the inhibitory effect on bladder carcinogenesis promotion via androgen signaling. Brassicasterol shows dual anti-infective properties against HSV-1 (IC50=1.2 µM) and Mycobacterium tuberculosis, and cardiovascular protective effect. Brassicasterol exerts an anti-cancer effect by dual-targeting AKT and androgen receptor signaling in prostate cancer.
  • HY-B1355AS
    Oxyphenbutazone-d9

    COX Bacterial Cancer Infection Inflammation/Immunology
    Oxyphenbutazone-d9 is the deuterium labeled Oxyphenbutazone. Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.
  • HY-B0269
    Rifapentine

    DL 473; Cyclopentylrifampicin

    Bacterial Antibiotic Infection
    Rifapentine (DL 473) is an antibiotic compound used in the treatment of tuberculosis.
  • HY-139695
    Spectinamide 1599

    Others Infection
    Spectinamide-1599 is a combination partner for anti-tuberculosis therapy.
  • HY-B0276
    Ethionamide

    2-Ethylthioisonicotinamide

    Bacterial Antibiotic Infection
    Ethionamide(2-ethylthioisonicotinamide) is an antibiotic used in the treatment of tuberculosis.
  • HY-76293
    I2906

    Bacterial Infection
    I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis.
  • HY-105099
    Rifalazil

    KRM-1648; ABI-1648

    DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pyloriC. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).
  • HY-144737
    Anti-inflammatory agent 15

    Bacterial TNF Receptor Infection Inflammation/Immunology
    Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research.
  • HY-144727
    Anti-inflammatory agent 11

    Bacterial TNF Receptor Infection Inflammation/Immunology
    Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research.
  • HY-B0271S
    Pyrazinamide-d3

    Pyrazinecarboxamide-d3; Pyrazinoic acid amide-d3

    Bacterial Autophagy Antibiotic Infection
    Pyrazinamide-d3 is deuterium labeled Pyrazinamide. Pyrazinamide (Pyrazinecarboxamide; Pyrazinoic acid amide) is a potent and orally active antitubercular antibiotic. Pyrazinamide is a prodrug that is converted to the active form pyrazinoic acid (POA) by PZase/nicotinamidase encoded by the pncA gene in M. tuberculosis.
  • HY-76260
    Faropenem sodium

    Bacterial Antibiotic Infection
    Faropenem sodium is an orally bioavailable penem antibiotic which can efficiently kill Mycobacterium tuberculosis.
  • HY-14881A
    Bedaquiline fumarate

    R403323; TMC207 fumarate; R207910 fumarate

    Bacterial Antibiotic Infection
    Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.
  • HY-112091
    GSK2200150A

    Bacterial Infection
    GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.
  • HY-13579A
    BTZ043 Racemate

    BTZ10526038; Benzothiazinone 10526038

    Bacterial Infection
    BTZ043 Racemate (BTZ10526038) is the racemate of BTZ043. BTZ043 is an inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), and the antimicrobial activity of BTZ043 is more potent than BTZ043 Racemate.
  • HY-B0306
    Prothionamide

    Protionamide

    Bacterial Antibiotic Infection
    Protionamide (or prothionamide) is a drug used in the treatment of tuberculosis; has also been tested for use in the treatment of leprosy.
  • HY-76210
    5-Hydroxypyrazine-2-Carboxylic Acid

    Bacterial Antibiotic Others
    5-Hydroxypyrazine-2-Carboxylic Acid, a metabolite of anti-tuberculosis drug pyrazinamide (PZA).
  • HY-100725
    BM212

    Bacterial Infection
    BM212 is a potent Mycobacterial membrane protein Large 3 (MmpL3) inhibitor. BM212 has strong bactericidal activity against both M. tuberculosis and some nontuberculosis mycobacteria. BM212 exhibits antimycobacterial activity against M. tuberculosis H37Rv with an MIC of 5 µM.
  • HY-17566
    Capreomycin sulfate

    Bacterial Antibiotic Infection
    Capreomycin sulfate is a peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis.
  • HY-W039897
    Methyl α-D-mannopyranoside

    Others Inflammation/Immunology
    Methyl α-D-mannopyranoside could target macrophages in anti-tuberculosis inhalation therapy.
  • HY-114439
    MtbHU-IN-1

    Bacterial Infection
    MtbHU-IN-1 is an inhibitor of Mycobacterium tuberculosis nucleoid-associated protein HU (MtbHU), with a Kd of 98 nM for binding to WT MtbHU.
  • HY-N1103A
    Vasicine hydrochloride

    Peganine hydrochloride

    Bacterial Infection Inflammation/Immunology
    Vasicine hydrochloride (peganine hydrochloride) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity.
  • HY-I0447A
    Sodium 4-aminosalicylate dihydrate

    4-Aminosalicylic acid sodium salt dihydrate

    Bacterial Antibiotic Infection
    Sodium 4-aminosalicylate dihydrate (4-Aminosalicylic acid sodium salt dihydrate) is one of the antimycobacterial drugs currently used for multidrug-resistant tuberculosis.
  • HY-N1103
    Vasicine

    Peganine

    Bacterial Inflammation/Immunology
    Vasicine (peganine) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity.
  • HY-10844
    Pretomanid

    PA-824; (S)-PA 824

    Bacterial Antibiotic Infection Cancer
    Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 µg/mL.
  • HY-108941
    Salicyl-AMS

    Bacterial Infection
    Salicyl-AMS is a mycobactin biosynthesis inhibitor which can also inhibit M. tuberculosis growth in vitro under iron-limited conditions.
  • HY-107775
    GSK656

    Bacterial Infection
    GSK656 is a potent antitubercular agent, acting as an inhibitor of Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS), with an IC50 of 0.2 μM.
  • HY-142031
    4-Piperidinecarboxamide

    Bacterial Infection
    4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent.
  • HY-N2033
    Chebulinic acid

    DNA/RNA Synthesis TGF-beta/Smad Proton Pump Infection
    Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
  • HY-B0276S
    Ethionamide-d3

    2-ethylthioisonicotinamide-d3

    Bacterial Antibiotic Infection
    Ethionamide-d3 (2-ethylthioisonicotinamide-d3) is the deuterium labeled Ethionamide. Ethionamide (2-ethylthioisonicotinamide) is an antibiotic used in the treatment of tuberculosis.
  • HY-B0269S
    Rifapentine-d9

    DL 473-d9; Cyclopentylrifampicin-d9

    Bacterial Antibiotic Infection
    Rifapentine-d9 (DL 473-d9) is the deuterium labeled Rifapentine. Rifapentine (DL 473) is an antibiotic compound used in the treatment of tuberculosis.
  • HY-126140
    MDRTB-IN-1

    Bacterial Infection
    MDRTB-IN-1 (5aα) is an antibiotic which is against Mycobacterium tuberculosis H37Rv with a MIC90 value of 10.5 μM.
  • HY-126131
    anti-TB agent 1

    Bacterial Infection
    anti-TB agent 1 is a potent and orally active anti-tuberculosis agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH.
  • HY-109588
    NITD-349

    Bacterial Infection
    NITD-349 is an MmpL3 inhibitor that shows highly potent anti-mycobacterial activity with MIC50 of 23 nM against virulent Mycobacterium tuberculosis H37Rv.
  • HY-109587
    BM635

    Bacterial Infection
    BM635 is a MmpL3 inhibitor with outstanding anti-mycobacterial activity. BM635 has an MIC50 of 0.12 μM against M. tuberculosis H37Rv.
  • HY-101040
    Q203

    IAP6; Telacebec

    Bacterial Antibiotic Infection
    Q203 (IAP6) is a midazopyridine amide compound. Q203 is active against Mycobacterium tuberculosis H37Rv with an MIC50 of 2.7 nM in culture broth medium.
  • HY-10844S
    Pretomanid-d4

    Bacterial Antibiotic Infection Cancer
    Pretomanid-d4 (PA-824-d4) is the deuterium labeled Pretomanid. Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 µg/mL.
  • HY-W028047
    JFD01307SC

    Bacterial Infection Inflammation/Immunology
    JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis.
  • HY-112702
    CRS400393

    Bacterial Infection
    CRS400393 is a potent antimycobacterial agent, with MIC of 0.03, 2, and ≤ 0.12 µg/mL against M. abs., M. avium, M. intracellulare, and M. tuberculosis, respectively.
  • HY-N0872
    Isosteviol

    (-)-Isosteviol; iso-Steviol

    Reactive Oxygen Species Topoisomerase Cardiovascular Disease Cancer
    Isosteviol ((-)-Isosteviol) is a derivative of Stevioside through acid catalyzed hydrolysis of Stevioside. Isosteviol inhibits DNA polymerase and DNA topoisomerase and has antibacterial, anticancer and anti-tuberculosis effects.
  • HY-146652
    UGM-IN-3

    Bacterial Infection
    UGM-IN-3 (compound 10a) is a UDP-galactopyranose mutase (UGM) inhibitor with a Kd of 66 μM. UGM-IN-3 inhibits the growth of Mycobacterium tuberculosis with a MIC value of 6.2 μg/mL.
  • HY-139654
    α/β-Hydrolase-IN-1

    Others Infection
    α/β-Hydrolase-IN-1 exhibits the best-in-class MICs of 50 μM (25 μg/mL) and 16 μM (8.4 μg/mL) against M. smegmatis and M. tuberculosis H37Ra, respectively.
  • HY-B1526
    Thiacetazone

    Thioacetazone; Amithiozone

    Bacterial Antibiotic Infection
    Thiacetazone (Thioacetazone) is a thiourea-containing antitubercular agent and is an orally active antibiotic. Thiacetazone has antibacterial action, which inhibits growth of Mycobacterium tuberculosis H37Rv with a MIC value of 0.1 μg/mL.
  • HY-B1355AS1
    Oxyphenbutazone-13C6

    COX Bacterial Cancer Infection Inflammation/Immunology
    Oxyphenbutazone-13C6 is the 13C6 labeled Oxyphenbutazone. Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.
  • HY-146107
    Antitubercular agent-23

    Bacterial Fungal Infection
    Antitubercular agent-23 (Compound 3a) is a potent anticandidiasis and antitubercular agent with MIC values of 1.1 µg/ml and 1 µg/ml against Candida albicans MTCC 3017 and M. tuberculosis (H37Rv), respectively.
  • HY-146106
    Antitubercular agent-22

    Bacterial Fungal Infection
    Antitubercular agent-22 (Compound 2) is a potent anticandidiasis and antitubercular agent with MIC values of 2.34 µg/ml and 2 µg/ml against Candida albicans MTCC 3017 and M. tuberculosis (H37Rv), respectively.
  • HY-147876
    Antimicrobial agent-3

    Bacterial Fungal Infection
    Antimicrobial agent-3 (Compound U10) is an antimicrobial agent against bacterial, fungal and tubercular infections.
  • HY-N1377
    Nevadensin

    Bacterial Infection Metabolic Disease Inflammation/Immunology
    Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive.
  • HY-19915
    Contezolid

    MRX-I

    Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI).
  • HY-100531
    DprE1-IN-2

    Bacterial Infection
    DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC50 of 28 nM. DprE1-IN-2 has antituberculosis effect.
  • HY-144735
    Anti-inflammatory agent 14

    Bacterial Infection Inflammation/Immunology
    Anti-inflammatory agent 14 (compound 28) is an anti-inflammatory agent, with a MIC50 of 2 μM for Mtb H37Rv.
  • HY-139594
    Polyketide synthase 13-IN-1

    Others Infection Inflammation/Immunology
    Polyketide synthase 13-IN-1 (compound 32) is a polyketide synthase 13 inhibitor.
  • HY-147263
    Dovramilast

    CC-11050

    Phosphodiesterase (PDE) Infection Inflammation/Immunology
    Dovramilast (CC-11050) is an oral phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast (CC-11050), as an adjunct, is used for the research of tuberculosis (TB).
  • HY-146448
    PXYD3

    Bacterial Infection
    PXYD3 is a ribosomal protein S1 (RpsA) antagonist with Kds of 5.66 and 6.91 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
  • HY-109587B
    BM635 mesylate

    Bacterial Infection
    BM635 mesylate is a MmpL3 inhibitor with outstanding anti-mycobacterial activity. BM635 mesylate has a MIC50 of 0.6 μM against M. tuberculosis  H37Rv. BM635 mesylate significantly improves the bioavailability compared to free-base BM635.
  • HY-12930
    SPR719

    VXc-486

    Topoisomerase Bacterial Infection
    SPR719 (VXc-486) is a gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively.
  • HY-N1976
    (+)-(3R,8S)-Falcarindiol

    (3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol

    Bacterial Cancer Infection Inflammation/Immunology
    (+)-(3R,8S)-Falcarindiol is a polyacetylene found in carrots, has antimycobacterial activity, with an IC50 of 6 μM and MIC of 24 μM against Mycobacterium tuberculosis H37Ra. Antineoplastic and anti-inflammatory activity.
  • HY-W013186S
    Lansoprazole Sulfide D4

    Proton Pump Bacterial Inflammation/Immunology
    Lansoprazole Sulfide D4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth.
  • HY-100654
    10-DEBC hydrochloride

    Akt Bacterial Infection Inflammation/Immunology
    10-DEBC hydrochloride is a selective Akt inhibitor, with an IC50 of 1.28 μM. 10-DEBC hydrochloride is a novel anti-TB compound.
  • HY-19750
    TBA-7371

    Bacterial Infection
    TBA-7371 is a potent, noncovalent DprE1 inhibitor. TBA-7371 has potent antitubercular activity .
  • HY-N3075
    Phytol

    (E)​-​Phytol

    Parasite Bacterial Infection
    Phytol ((E)​-​Phytol), a diterpene alcohol from chlorophyll widely used as a food additive and in medicinal fields, possesses promising antischistosomal properties. Phytol has antinociceptive and antioxidant activitiesas well as anti-inflammatory and antiallergic effects. Phytol has antimicrobial activity against Mycobacterium tuberculosis and Staphylococcus aureus.
  • HY-109587A
    BM635 hydrochloride

    Bacterial Infection
    BM635 hydrochloride is a MmpL3 inhibitor with outstanding anti-mycobacterial activity. BM635 hydrochloride has an MIC50 of 0.08 μM against M.tuberculosis H37Rv. BM635 hydrochloride doubles the in vivo exposure with respect to the free base BM635.
  • HY-N0262
    Cordycepin

    3'-Deoxyadenosine

    MMP Bacterial Autophagy Antibiotic Cancer Infection Inflammation/Immunology
    Cordycepin (3'-Deoxyadenosine) is a nucleoside derivative and inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase.
  • HY-146489
    Anti-infective agent 3

    Bacterial Parasite Infection
    Anti-infective agent 3 (compound 3l) shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC50 values of 0.47 and 0.13 μM, respectively. Anti-infective agent 3 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 4 μg/mL.
  • HY-145379
    Miaosporone A

    Parasite Endogenous Metabolite Infection
    Miaosporone A, an angucyclic quinone, exhibits antimalarial activity against Plasmodium falciparum K1 and antibacterial activity against Mycobacterium tuberculosis with respective IC50 values of 2.5 and 2.4 μM and displays cytotoxic activities against both cancerous (MCF-7 and NCI-H187) and nonmalignant (Vero) cells.
  • HY-146488
    Anti-infective agent 2

    Parasite Bacterial Infection
    Anti-infective agent 2 (compound 3k) shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC50 values of 0.07 and 2.20 μM, respectively. Anti-infective agent 2 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 32 μg/mL.
  • HY-146487
    Anti-infective agent 1

    Bacterial Parasite Infection
    Anti-infective agent 1 (compound 3a) is a potent and selective antiprotozoal and antimycobacterial agent. Anti-infective agent 1 shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC50 values of 10.95 and 0.06 μM, respectively. Anti-infective agent 1 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 8 μg/mL.
  • HY-100750
    Norverapamil hydrochloride

    (±)-Norverapamil hydrochloride; D591 hydrochloride

    Calcium Channel P-glycoprotein Drug Metabolite Cardiovascular Disease
    Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
  • HY-12903
    Macozinone

    PBTZ169

    Bacterial Infection
    Macozinone (PBTZ169) is a bactericidal benzothiazinone and a potent DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) inhibitor. Macozinone inhibits the essential flavoprotein DprE1 by forming a covalent bond with the active-site Cys387 residue. Macozinone has antituberculosis effect.
  • HY-143473
    FabG1-IN-1

    Bacterial Infection
    FabG1-IN-1 (Compound 29) is a potent MabA (FabG1) inhibitor with an IC50 of 38 µM.
  • HY-135328
    Norverapamil

    (±)-Norverapamil; D591

    Calcium Channel P-glycoprotein Drug Metabolite Cardiovascular Disease
    Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
  • HY-111747
    TBAJ-587

    Bacterial Infection Cardiovascular Disease
    TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 µg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization.
  • HY-135328S
    Norverapamil-d7

    (±)-Norverapamil-d7; D591-d7

    Calcium Channel P-glycoprotein Drug Metabolite Cardiovascular Disease
    Norverapamil-d7 ((±)-Norverapamil-d7) is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
  • HY-146003
    FAAL-IN-1

    Bacterial Infection
    FAAL-IN-1 (compound 32) is a selective inhibitor of fatty acyl-AMP ligase (FAAL), with a Ki of 0.7 μM for FAAL28. FAAL-IN-1 shows antimycobacterial activity.
  • HY-150637
    Mab Aspartate Decarboxylase-IN-1

    Bacterial Infection
    Mab Aspartate Decarboxylase-IN-1 is a potent aspartate decarboxylase (PanD) inhibitor with an IC50 value of 56.3 µM. Mab Aspartate Decarboxylase-IN-1 shows antibacterial activity.
  • HY-N8060A
    Orotidine 5′-monophosphate trisodium

    Orotidine monophosphate trisodium; Orotidylic acid trisodium

    Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT).
  • HY-145286
    IMPDH2-IN-2

    Others Cancer Infection
    IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a Ki,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent.
  • HY-N0941
    beta-Mangostin

    β-Mangostin

    Bacterial Parasite Apoptosis Cancer Infection
    beta-Mangostin (β-Mangostin) is a xanthone compound present in Cratoxylum arborescens, with antibacterial and antimalarial activities. beta-Mangostin exhibits antimycobacterial activity against Mycobacterium tuberculosis with an MIC of 6.25 μg/mL. beta-Mangostin possesses in vitro antimalarial activity against Plasmodium falciparum, with an IC50 of 3.00 μg/mL. beta-Mangostin has potent anticancer activity against various cancers (such as hepatocellular carcinoma, leukaemic).
  • HY-147819
    DNA Gyrase-IN-3

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-3 (Compound 28) is a bacterial DNA gyrase B inhibitor with IC50s of 5.41-15.64 µM for E. coli DNA gyrase. Anti-tubercular and antibacterial activity.